Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: The cardiovascular health study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 952 KB, PDF-dokument
Circulating neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) have been independently associated with dementia risk. Their additive association, and their associations with dementia-specific mortality, have not been investigated.
METHODS
We associated serum NfL, GFAP, total tau ,and ubiquitin carboxyl-terminal hydrolase-L1, measured in 1712 dementia-free adults, with 19-year incident dementia and dementia-specific mortality risk, and with 3-year cognitive decline.
RESULTS
In adjusted models, being in the highest versus lowest tertile of NfL or GFAP associated with a hazard ratio (HR) of 1.49 (1.20–1.84) and 1.38 (1.15–1.66) for incident dementia, and 2.87 (1.79–4.61) and 2.76 (1.73–4.40) for dementia-specific mortality. Joint third versus first tertile exposure further increased risk; HR = 2.06 (1.60–2.67) and 9.22 (4.48–18.9). NfL was independently associated with accelerated cognitive decline.
DISCUSSION
Circulating NfL and GFAP may, independently and jointly, provide useful clinical insight regarding dementia risk and prognosis.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Alzheimer's and Dementia |
| Vol/bind | 19 |
| Udgave nummer | 12 |
| Sider (fra-til) | 5672-5680 |
| Antal sider | 9 |
| ISSN | 1552-5260 |
| DOI | |
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
A full list of principal CHS investigators and institutions can be found at CHS‐NHLBI.org. This research was supported by contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, N01HC15103, and 75N92021D00006, and grants U01HL080295 and U01HL130114 from the National Heart, Lung, and Blood Institute, with additional contributions from the National Institute of Neurologic Disorders and Stroke (UH2/UH3 NS017950 and UF1 NS125513) and the National Institute on Aging (NIA: R01AG20098, R01AG023629, and R01AG053325). Support for individual investigators include grants from the NIA (K24AG065525 to K.J.M., K01AG071689 to A.E.F., and P30 AG066546 to S.S. and C.L.S), the Novo Nordisk Foundation Challenge Programme (Harnessing the Power of Big Data to Address the Societal Challenge of Aging [NNF17OC0027812] to H.T.C., K.F.M., and M.K.J.), and the Alzheimer's Association (AARF‐21‐851606 to H.T.C.).
Publisher Copyright:
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
ID: 359850679